Santhera shares updates on commercial rollout of AGAMREE® [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Funding from National Health Service (NHS) England is now available for AGAMREE for the treatment of DMD, enabling prescribing in England to commence. This follows positive NICE (National Institute for Health and Care Excellence) final guidance for AGAMREE announced on January 16, 2025 and initial sales already achieved in Scotland and Wales. In addition, Santhera notes that Kye Pharmaceuticals, sub-licensee of its commercialization partner Catalyst Pharmaceuticals, has received acceptance by Health Canada for the New Drug Submission for AGAMREE with Priority Review. This potentially paves the way for the therapy to become the first approved treatment for DMD in Canada by the end of 2025. Dario Eklund, CEO of Santhera said : "I'm pleased to share the latest progress on the commercial rollout of AGAMREE, particularly in the UK, where a significant portion of our clinical trials were conducted. These trial sites played a key role in generating the data to support the approval. We a
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift [Yahoo! Finance]Yahoo! Finance
- BioFlorida Fuels Innovation: Awards $90,000 in Annual Pitch Competition [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
CPRX
Earnings
- 11/5/25 - Beat
CPRX
Sec Filings
- 12/16/25 - Form 4
- 12/12/25 - Form 144
- 12/10/25 - Form 4
- CPRX's page on the SEC website